Display options
Cite
Svensson LA. Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs. Pharm Res. 1985;2(4):156-62doi: 10.1023/A:1016379820412.
Svensson, L. A. (1985). Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs. Pharmaceutical research, 2(4), 156-62. https://doi.org/10.1023/A:1016379820412
Svensson, L A. "Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs." Pharmaceutical research vol. 2,4 (1985): 156-62. doi: https://doi.org/10.1023/A:1016379820412
Svensson LA. Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs. Pharm Res. 1985 Jul;2(4):156-62. doi: 10.1023/A:1016379820412. PMID: 24272805.
Copy Download .nbib Format: NLM
Share it on

Pharm Res. 1985 Jul;2(4):156-62. doi: 10.1023/A:1016379820412.

Sympathomimetic bronchodilators: increased selectivity with lung-specific prodrugs.

Pharmaceutical research

L A Svensson

Affiliations

  1. , .

PMID: 24272805 DOI: 10.1023/A:1016379820412

Abstract

The development of selective bronchodilator β-adrenoceptor agonists is reviewed with emphasis on a pharmacodynamic approach, which is directed to drugs with high specificity for the β2-adrenoceptor, and on a pharmacokinetic approach in which known β2-adrenoceptor agonists are converted to prodrugs with selectivity for the lung. The pharmacodynamic approach has produced drugs that display high specificity for the β2-adrenoceptor but still suffer from side-effects including tremor and palpitations. This is due to the fact that the β2-adrenoceptors present in skeletal muscle and blood vessel are indistinguishable from those in the airways. On the other hand, the prodrug pharmacokinetic approach offers a promising way to obtain selectively acting bronchodilators with significantly fewer side-effects.

References

  1. Xenobiotica. 1972 Jul;2(4):363-73 - PubMed
  2. Chest. 1984 Sep;86(3):404-8 - PubMed
  3. Pharm Res. 1984 Jan;1(1):19-23 - PubMed
  4. Am J Physiol. 1948 Jun;153(3):586-600 - PubMed
  5. Scand J Respir Dis. 1972;53(5):302-13 - PubMed
  6. Br J Pharmacol. 1972 Nov;46(3):458-72 - PubMed
  7. Allergy. 1981 Feb;36(2):115-22 - PubMed
  8. Biochem Pharmacol. 1978 Feb 1;27(3):301-5 - PubMed
  9. Acta Pharmacol Toxicol (Copenh). 1979;44 Suppl 2:36-40 - PubMed
  10. Allergy. 1979 Aug;34(4):221-4 - PubMed
  11. J Pharmacol Exp Ther. 1981 Feb;216(2):395-400 - PubMed
  12. Nature. 1967 May 6;214(5088):597-8 - PubMed
  13. Pharmacol Ther. 1981;14(1):25-53 - PubMed
  14. Experientia. 1969 Sep 15;25(9):899-901 - PubMed
  15. J Pharm Sci. 1976 Oct;65(10):1510-2 - PubMed
  16. Postgrad Med J. 1975;51(7 SUPPL):69-75 - PubMed
  17. Allergy. 1982 Jul;37(5):351-7 - PubMed
  18. J Pharm Sci. 1975 Feb;64(2):181-210 - PubMed
  19. Xenobiotica. 1973 Feb;3(2):113-20 - PubMed
  20. Br J Pharmacol. 1976 Jun;57(2):235-46 - PubMed
  21. J Pharmacol Exp Ther. 1978 Sep;206(3):515-27 - PubMed
  22. Scand J Respir Dis. 1977;58(1):5-10 - PubMed
  23. Br J Pharmacol. 1976 Sep;58(1):43-6 - PubMed
  24. Arch Int Pharmacodyn Ther. 1976 May;221(1):32-9 - PubMed
  25. Arch Int Pharmacodyn Ther. 1966 May;161(1):68-75 - PubMed
  26. Chest. 1980 Aug;78(2):283-7 - PubMed
  27. Drug Metab Dispos. 1976 Jan-Feb;4(1):72-8 - PubMed
  28. Arzneimittelforschung. 1979;29(6):967-70 - PubMed
  29. J Biol Chem. 1978 Jul 25;253(14):5090-102 - PubMed
  30. J Allergy Clin Immunol. 1977 Feb;59(2):93-100 - PubMed
  31. N Engl J Med. 1984 Jun 14;310(24):1570-9 - PubMed
  32. Arch Int Pharmacodyn Ther. 1975 Oct;217(2):218-35 - PubMed
  33. Eur J Clin Pharmacol. 1977 Jul 19;11(6):429-33 - PubMed
  34. Am Rev Respir Dis. 1984 Sep;130(3):357-62 - PubMed
  35. Drugs. 1977 Jul;14(1):1-28 - PubMed
  36. Nature. 1968 Aug 24;219(5156):862-3 - PubMed
  37. Am J Med Sci. 1967 Mar;253(3):321-4 - PubMed

Publication Types